(±)-Salsolinol (hydrochloride)
目录号 : GC13786
A metabolite of ethanol that targets dopaminergic neurons
Cas No.:79923-51-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
(±)-Salsolinol targets depolarize dopamineric neurons.
Dopaminergic neurons produce dopamine, a neurotransmitter with various roles in neurological functions. Progressive loss of dopaminergic neurons is considered as the cause of many motor symptoms associated with Parkinson’s disease.
In vitro: A previous study found that (±)-salsolinol could activate the μ-opioid receptor by the classical G protein-adenylate cyclase pathway. The agonist action of (±)-salsolinol was blocked by the μ-opioid antagonist. The EC50 for the purified stereoisomers (R)- salsolinol and (S)-salsolinol were 6 × 10-4 M and 9 × 10-6 M, respectively. It was found that (±)-salsolinol did not promote the recruitment of β-arrestin. Molecular docking studies showed that the interaction of (R)- and (S)-salsolinol with the μ-opioid receptor was similar to that predicted for the agonist morphine [1].
In vivo: Male Wistar rats were subjected to continuous i.p. dosing of salsolinol at 200 mg/kg for 2 or 4 weeks with either high-fat or normal diet. Results showed that salsolinol could reduce total body mass significantly with no differences in total food intake. In addition, the epididymal fat pad weight over final body mass ratio was lower in salsolinol treated rats with high fat diet. Moreover, the perimeter, e area, as well as short and long axis of the fad pad adipocytes decreased in salsolinol treated animals significantly [2].
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Berríos-Cárcamo P, Quintanilla ME, Herrera-Marschitz M, Vasiliou V, Zapata-Torres G, Rivera-Meza M. Racemic Salsolinol and its Enantiomers Act as Agonists of the μ-Opioid Receptor by Activating the Gi Protein-Adenylate Cyclase Pathway. Front Behav Neurosci. 2017 Jan 23;10:253. doi: 10.3389/fnbeh.2016.00253. eCollection 2016.
[2] Aleksandrovych V, Kurnik M, Biaas M, Bugajski A, Thor P, Gil K. The effect of peripheral chronic salsolinol administration on fat pad adipocytes morphological parameters. Folia Med Cracov. 2016;56(1):81-95.
| Cas No. | 79923-51-6 | SDF | |
| 化学名 | 1,2,3,4-tetrahydro-1-methyl-6,7-isoquinolinediol, monohydrochloride | ||
| Canonical SMILES | CC1NCCC2=C1C=C(O)C(O)=C2.Cl | ||
| 分子式 | C10H13NO2 • HCl | 分子量 | 215.7 |
| 溶解度 | Soluble in ethanol;Soluble in DMSO;Soluble in Water | 储存条件 | Store at 4°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.6361 mL | 23.1803 mL | 46.3607 mL |
| 5 mM | 0.9272 mL | 4.6361 mL | 9.2721 mL |
| 10 mM | 0.4636 mL | 2.318 mL | 4.6361 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。